Plain-English translation of NCT06456450 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world research study that follows adults with severe asthma who are being treated with biologic medications like omalizumab, mepolizumab, benralizumab, dupilzumab, or tezepelumab. Researchers want to understand how well these medications actually work for patients, whether some people need to switch medications, and what factors help predict which treatment will work best for each person.
Severe asthma can be hard to control even with standard treatments, and newer biologic medications offer hope—but doctors need real-world information about which patients benefit most and when switching to a different medication might help. This study will gather that practical knowledge to improve treatment decisions.
You likely qualify if…
You likely don't qualify if…
As a participant, you would be followed over time as you receive your prescribed biologic medication—researchers are not asking you to change your treatment or do anything different than your normal care. Instead, they will collect information from your medical visits and records to track how well the medication is working, whether you have any side effects, and whether you eventually need to switch to a different biologic. The study involves multiple hospital centers in Taiwan, so your involvement would continue as long as you are receiving this treatment.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Taiwan